Krystal Biotech (KRYS) PT Raised to $35 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
October 15, 2018 7:45 AM EDTKB103 is Krystals first "off-the-shelf", topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.
Results on 2 patients met all primary efficacy (presence of functional COL7 expression, observation of NC1 and NC2 reactive anchoring fibrils and continued expression following repeat administration) and safety endpoints (no adverse events, inflammation or irritation) in topically administered KB103 wounds.
With respect to secondary endpoints topically administered KB103 wounds closed in 2 weeks and continue to stay closed to date. Topically administered placebo administered wounds took 10 weeks to close in patient 1 and did not completely close throughout the... More
